News

April 25, 2019

Aubagio Lowers Relapse Rate in RRMS Patients, Real-world Observational Study Shows

News

In clinical practice, relapse events dropped by roughly half over a four-year period in relapsing-remitting multiple sclerosis (RRMS) patients treated with Aubagio (teriflunomide), a real-world study reports. The study, “Real-life outcomes of ... Read more

April 24, 2019April 24, 2019

MS Trust Promotes Multiple Initiatives in UK to Encourage Exercise

Alexa, News

The Multiple Sclerosis Trust, a charity organization that provides support to MS patients in the United Kingdom, is urging them to remain active and find ways to introduce physical ... Read more

April 24, 2019April 24, 2019

Thyroid Hormone Mimetic Holds Promise as Remyelination Therapy for MS, Mouse Study Shows

News

Researchers have developed a compound based on the thyroid hormone T3 that is able to repair damaged myelin in the brain of mice, a discovery that holds promise for ... Read more

April 23, 2019April 23, 2019

Main Ingredient in Potential MS Therapy EHP-101 Not a Controlled Substance, DEA Rules

News

The U.S. Drug Enforcement Administration (DEA) has determined that the cannabidiol-based active ingredient of EHP-101, an investigational oral treatment for multiple sclerosis (MS) under development by Emerald Health Pharmaceuticals (EHP), should not ... Read more

April 23, 2019April 24, 2019

Study Will Explore Benefits of Tai Chi, Meditation on MS Patients’ Physical Balance

News

A pilot study has been launched to assess the immediate and enduring benefits of tai chi and mindfulness meditation on the physical balance and mental wellness of people with multiple ... Read more

April 22, 2019April 22, 2019

Two-year Efficacy with Short-course Treatment Sets Mavenclad Apart, EMD Serono Executive Says

News

Mavenclad (cladribine) tablets stand out as a treatment for relapsing forms of multiple sclerosis (MS), providing two years of proven efficacy with a maximum of 20 days of oral treatment, a top ... Read more

April 22, 2019April 22, 2019

14 Notable Pilot Projects Among Research Efforts Funded by National MS Society

News

The National Multiple Sclerosis Society has recently awarded $24.4 million in grants to support 64 research projects on multiple sclerosis (MS) worldwide, including $750,000 to fund 14 high-risk, high-reward pilot projects ... Read more

April 18, 2019April 22, 2019

Oligodendrocyte Precursor Cells Disrupt Blood-brain Barrier, Trigger Brain Inflammation in MS, Study Shows

News

Oligodendrocyte precursor cells (OPCs), the cells responsible for myelin production, are unable to migrate into sites of myelin loss in the brain. These cells then cluster and disrupt the ... Read more

April 18, 2019April 18, 2019

EMA Reviewing Safety Data for Lemtrada After Reports of Serious Treatment Side Effects

News

The European Medicines Agency (EMA) is reviewing safety data for Sanofi Genzyme‘s Lemtrada (alemtuzumab) following new reports of serious treatment side effects. Lemtrada is a humanized monoclonal antibody used to slow ... Read more

April 17, 2019April 17, 2019

National MS Society Grants $24.4M to Fund 64 MS Research Projects

News

The National Multiple Sclerosis Society has granted $24.4 million to fund 64 multiple sclerosis (MS) research projects and training fellowships worldwide. This is the latest funding initiative by the Society, ... Read more

April 17, 2019April 17, 2019

First Large-scale Clinical Genomic Research Study Aims to Improve Personalized MS Treatment

News

A collaboration between DNAnexus, the Sutter Health network, and the University Pittsburgh Medical Center (UPMC) aims to improve personalized medicine in multiple sclerosis (MS) through the first large-scale clinical genomic ... Read more

April 16, 2019April 16, 2019

Life Partners of RRMS Patients Experience High Strain Even in Early Disease Stages, Study Finds

News

Cognitive and neuropsychiatric problems caused by relapsing-remitting multiple sclerosis (RRMS) — such as memory and processing issues, depression, and irritability — are the main source of strain among life ... Read more

April 16, 2019April 16, 2019

Trial Testing Deprexis Online Therapy for MS-related Depression Enrolling in US, Germany

News

A clinical trial testing a computer program called Deprexis as a home-based therapeutic strategy for multiple sclerosis (MS)-related depression is enrolling participants with all types of MS  at three sites ... Read more

April 15, 2019April 18, 2019

Web Portal That Detects Cognitive Changes via Language Tests Detailed in Study

News

A new web portal called Talk2Me that detects early changes in language could help doctors diagnose or determine progression in neurodegenerative disorders like multiple sclerosis, the scientists who created it ... Read more

April 15, 2019April 15, 2019

Anne Cross, Neurologist with Pioneering Work into B-cells and MS, Awarded John Dystel Prize

News

This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the department of neuroimmunology at  Washington University School of Medicine ... Read more

April 12, 2019April 12, 2019

TMEM10 in Demyelinated MS Lesions May Contribute to Remyelination, Study Suggests

News

A protein that promotes nervous system repair through remyelination — the creation of myelin, the protective sheath around nerve cells — in mice also is found in remyelinating plaques ... Read more

April 12, 2019April 18, 2019

Excess Body Fat Spurs Disease Progression by Impact on Immune Cells, Study Suggests

News

A link between fat molecules called ceramides and worsening disease in overweight and obese people with multiple sclerosis appears to exist, a study reports, with its findings suggesting that ceramides prompt ... Read more

April 11, 2019April 18, 2019

Higher Vitamin D Levels in Rituximab-treated MS Patients Linked to Lower Inflammatory Activity, Study Suggests

News

Rituximab-treated multiple sclerosis (MS) patients who take vitamin D supplements have less inflammatory activity, a study reports. Increased levels of vitamin D were associated with beneficial treatment outcomes, such as ... Read more

April 11, 2019April 11, 2019

Tecfidera Better at Preventing Relapses than Aubagio, Real-world Study Suggests

News

Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study. The study “Comparative effectiveness of teriflunomide and dimethyl ... Read more

April 10, 2019April 18, 2019

MS Misdiagnosis Too Common, Puts Patients in Unnecessary Peril from Therapies, Study Reveals

News

Nearly 18% of new multiple sclerosis (MS) patients referred to two speciality clinics in Los Angeles, California, had been misdiagnosed with the disease, according to a recent study. Most ... Read more

April 10, 2019April 11, 2019

Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says

News

The effectiveness of Mayzent (siponimod) in both the brain and the body make it an oral therapy tailored for people with early secondary progressive multiple sclerosis (SPMS), according to Dan Bar-Zohar, ... Read more

April 9, 2019April 9, 2019

U.K. Implements Stricter Rules for Gabapentin, Pregabalin Prescriptions

News

Gabapentin and pregabalin now have more restrictive rules for prescriptions in the United Kingdom. Because of concerns regarding the medications’ misuse, both were classified as class C controlled medicines. ... Read more

April 9, 2019April 9, 2019

Menstruation Onset, Pregnancies and Breastfeeding Habits Don’t Influence MS Risk, Study Suggests

News

A woman’s age at her first menstruation, or becoming pregnant and breastfeeding does not substantially influence the long-term risk of multiple sclerosis (MS) or the risk of increased disability, ... Read more

April 8, 2019

In-Depth Study into MS Progression Gets $2M Boost from Roche Canada

News

Roche Canada is contributing $2.125 million to the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), a partnership initiative with the Multiple Sclerosis Society of Canada, the ... Read more

April 8, 2019April 12, 2019

Mayzent ‘Will Change Lives’ of MS Patients Transitioning to SPMS, Novartis Says

News

The “regulatory environment” favored Mayzent (siponimod) being approved as an oral treatment for people with relapsing multiple sclerosis (MS) — specifically, clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive MS (SPMS) — a top ... Read more

April 5, 2019April 5, 2019

#AAN2019 — Mineral Intake Not Linked to MS Risk, Study Suggests

News

The amount of zinc, iron, and other minerals a person has in his or her diet is not associated with the risk of developing multiple sclerosis (MS), according to ... Read more

April 4, 2019April 4, 2019

#AAN2019 — Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows

News

Treatment with oral ibudilast slows brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase ... Read more

April 4, 2019April 4, 2019

CMSC Announces Technology Contests to Improve MS Patients’ Quality Of Life

News

The Consortium of Multiple Sclerosis Centers (CMSC) announced two contests that will be featured at its Annual Meeting, May 28–June 1 in Seattle, Washington. The contests, called “Design for Rehabilitation — Take ... Read more

April 3, 2019April 8, 2019

Cleveland Clinic Neurologist Applauds Mayzent’s FDA Approval, But Surprised by Those It May Not Treat

News

When the U.S. Food and Drug Administration approved the disease-modifying therapy Mayzent for relapsing types of multiple sclerosis, it specified in its label that the treatment was for people with clinically isolated syndrome, relapsing-remitting ... Read more

April 3, 2019April 3, 2019

Veterans Affairs and National MS Society Team Up to Better Care for Vets with This Disease

News

Complementing its nationwide network of multiple sclerosis (MS) research and clinical services centers, the U.S. Department of Veterans Affairs (VA) has teamed up with the National Multiple Sclerosis Society (NMSS) ... Read more

April 2, 2019

Review of 2 Diets That May Benefit MS Patients: A Nutritionist’s View

News

I recently came across the article “Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic,” published in the journal Nutrients, which ... Read more

April 2, 2019April 2, 2019

Analysis of TWEAK Protein Levels May Help Identify Active Inflammation in MS Patients, Study Suggests

News

High blood levels of a signaling protein known as TWEAK are associated with active neuroinflammation in patients with multiple sclerosis (MS), a study shows. This finding suggests that TWEAK ... Read more

April 2, 2019April 2, 2019

NeurologyLive Launches Series of Educational Videos About MS

News

NeurologyLive has launched a series of educational videos intended to provide an overview of the diagnositic methods and treatment options available to multiple sclerosis (MS) patients. The video series, “Advances in the ... Read more

April 1, 2019April 1, 2019

Tiny DNA Molecule May Help Development of Myelin Repair Therapies, Study Suggests

News

A shortened DNA molecule showed an increased ability to bind myelin in human cells, and may boost the development of remyelination approaches for multiple sclerosis (MS) treatment, according to ... Read more

April 1, 2019April 18, 2019

FDA Approves EMD Serono’s Mavenclad as Treatment for RRMS and Active SPMS

News

The U.S. Food and Drug Administration has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS (RRMS) and active secondary ... Read more

March 29, 2019March 29, 2019

$1.5M Earmarked for MS Research on Cannabis in Canada

News

In partnership with the Canadian Institutes of Health Research, the MS Society of Canada has announced $1.5 million to fund research over five years on the effects of cannabis on multiple sclerosis ... Read more

March 29, 2019March 29, 2019

Mediaplanet Features MS Patient and Former NHL Player Bryan Bickell in Awareness Effort

News

MediaPlanet has launched a robust multimedia campaign aimed at calling attention to multiple sclerosis (MS) and similar diseases and featuring MS patient and former professional hockey player Bryan Bickell. ... Read more

March 28, 2019April 4, 2019

MS Patient Groups React Favorably to Mayzent Approval, But Question Therapy’s Price Tag

News

National organizations that represent patients with multiple sclerosis (MS) welcome the U.S. Food and Drug Administration’s March 26 approval of Novartis’ oral therapy Mayzent (siponimod) — but they complain that, at $88,500 per ... Read more

March 28, 2019March 28, 2019

Fatigue is Normal When Caring for a Loved One with MS but it’s Unsustainable, Expert Says

News

Caring for a loved one with multiple sclerosis (MS) can be exhausting, resulting in crankiness, sleepless nights, and excessive sadness, but many resources are available to help deal with the ... Read more

March 27, 2019March 27, 2019

Celgene Seeking FDA Approval for Ozanimod to Treat Adults With Relapsing MS

News

An application has been submitted to approve ozanimod as an oral treatment for adults with relapsing forms of multiple sclerosis in the U.S., according to its developer, Celgene. “New oral treatment options ... Read more